Skip to main content
Fig. 7 | Journal of Neuroinflammation

Fig. 7

From: Teriflunomide attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations

Fig. 7

Teriflunomide treatment prevents but does not reverse retinal ganglion cell loss in PLPmut mice. a Cresyl violet-labeled perikarya in the ganglion cell layer of flat-mounted retinae from Wt, untreated mutants (PLPmut), preventively treated mutants (150 days, starting from postnatal month 4; PLPmut + teriflunomide preventive) and PLPmut mice after treatment interruption at 75 days after treatment onset (PLPmut + teriflunomide terminated). Mice were investigated at 9 months of age. b Quantification of cresyl violet-labeled perikarya in the ganglion cell layer of flat-mounted retinae of Wt and PLPmut mice and of PLPmut mice after 150 days of preventive treatment. The numbers of cresyl violet-labeled perikarya were significantly reduced in the untreated PLPmut mice, but significantly rescued upon preventive treatment. Mice were investigated at 9 months of age. c Quantification of cresyl violet-labeled perikarya in the ganglion cell layer of flat-mounted retinae of PLPmut mice after 75 days of preventive treatment, followed by 75 days without treatment. Rescue of cresyl violet-labeled perikarya persisted after treatment termination. Mice were investigated at 9 months of age. d Depiction of cresyl violet-labeled perikarya in the ganglion cell layer (left) and their quantification (right) in Wt and PLPmut mice and in PLPmut mice after 150 days of therapeutic treatment (PLPmut + teriflunomide therapeutic) starting at 10 months of age. Therapeutic treatment did not significantly reverse retinal ganglion cell loss in PLPmut mice. Mice were investigated at 15 months of age. Scale bar, 50 μm. One-way ANOVA and Tukey’s post hoc tests. *P < 0.05, **,##P < 0.01, ***P < 0.001. n = 5 mice per group

Back to article page